<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lori Laffel, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Britta Svoren, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph I Wolfsdorf, MD, BCh</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The incidence of type 2 diabetes mellitus (T2DM) in youth has increased in many countries since the early 1990s and is linked to the rise in childhood obesity. T2DM and its comorbidities are risk factors for vascular disease later in life and premature mortality. As a result, it is imperative for clinicians to identify and treat children and adolescents with this disease.</p><p>The epidemiology, presentation, and diagnosis of T2DM in children and adolescents are presented here. Other aspects of T2DM in youth are discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1774.html" rel="external">"Prevention of type 2 diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5821.html" rel="external">"Management of type 2 diabetes mellitus in children and adolescents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5826.html" rel="external">"Chronic complications and screening in children and adolescents with type 2 diabetes mellitus"</a>.)</p><p></p><p class="headingAnchor" id="H14731063"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>T2DM is characterized by hyperglycemia, insulin resistance, and also relative impairment in insulin secretion. The presence of insulin resistance explains the strong clinical association of T2DM with obesity and other insulin-resistant states (see <a class="local">'Risk factors'</a> below). Impaired insulin secretion has been demonstrated in a variety of studies, which show that patients usually have lost approximately 80 percent of their pancreatic beta cell function before the diagnosis of T2DM [<a href="#rid1">1,2</a>]. In most cases, the impaired insulin secretion does not appear to be mediated by antibodies against the pancreatic islet cells. (See  <a class="medical medical_review" href="/z/d/html/1810.html" rel="external">"Pathogenesis of type 2 diabetes mellitus"</a>.)</p><p>By contrast, type 1 diabetes mellitus (T1DM) is primarily characterized by absolute insulin deficiency, usually caused by T cell-mediated immune destruction of pancreatic beta cells. Insulin resistance may be present to a variable degree. (See  <a class="medical medical_review" href="/z/d/html/1800.html" rel="external">"Pathogenesis of type 1 diabetes mellitus"</a>.)</p><p>Despite these apparent differences, there is considerable clinical overlap between T2DM and T1DM regarding both insulin resistance and presence of pancreatic autoantibodies. There may be considerable clinical overlap between T2DM and T1DM, and, at the time of presentation, it may be difficult to distinguish between them. Insulin resistance can be present in T1DM. The presence of pancreatic autoantibodies, however, is considered diagnostic of T1DM. (See <a class="local">'Type 2 versus type 1 diabetes'</a> below and  <a class="medical medical_review" href="/z/d/html/1793.html" rel="external">"Classification of diabetes mellitus and genetic diabetic syndromes"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H270057004"><span class="h2">Incidence and trends</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diabetes</strong> – The incidence of T2DM among youth is increasing in many countries, coinciding with increasing prevalence of obesity and severe obesity. As an example, in the United States, there was a sharp rise in T2DM from 9.0 cases per 100,000 in 2002-2003 to 13.8 cases per 100,000 in 2014-2015, with an adjusted annual increase of T2DM of 4.8 percent  (<a class="graphic graphic_figure graphicRef132197" href="/z/d/graphic/132197.html" rel="external">figure 1</a>), based on a large representative dataset from the SEARCH for Diabetes in Youth study [<a href="#rid3">3</a>]. Similarly, the proportion of new cases of diabetes in youth classified as T2DM was negligible before 1980s, then rose substantially in Japan [<a href="#rid4">4</a>], Thailand [<a href="#rid5">5</a>], Argentina [<a href="#rid6">6</a>], and other countries [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1">The increasing trends in T2DM among youth appear to lag, as expected, behind the increase in obesity among adolescents. One explanation is that there is a latency period between the onset of obesity and the related risk for T2DM [<a href="#rid8">8</a>]. Consistent with this model, studies have shown sharp increases in T2DM among young adults [<a href="#rid9">9</a>]. Thus, the rates of obesity among adolescents may cause a modest increase in T2DM among adolescents and a more substantial increase in T2DM when the cohort reaches adulthood. Furthermore, T2DM may be most closely correlated with severe obesity, which continues to rise among adolescents in the United States [<a href="#rid10">10</a>]. Finally, changes in demographics also may contribute to the increased prevalence of T2DM in the United States, with increases in racial and ethnic groups that experience higher rates of T2DM and/or ongoing increases in the prevalence or severity of obesity in some segments of the population. (See  <a class="medical medical_review" href="/z/d/html/5874.html" rel="external">"Definition, epidemiology, and etiology of obesity in children and adolescents", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1">The burden of T2DM varies markedly among racial/ethnic groups  (<a class="graphic graphic_figure graphicRef95197" href="/z/d/graphic/95197.html" rel="external">figure 2</a>) [<a href="#rid11">11</a>]. As an example, the incidence of T2DM in United States children ages 10 to 19 years in 2014-2015 was [<a href="#rid3">3</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Non-Hispanic White youth – 4.5 per 100,000</p><p class="bulletIndent2"><span class="glyph">•</span>Asian/Pacific Islander youth – 11.9 per 100,000</p><p class="bulletIndent2"><span class="glyph">•</span>Hispanic youth – 20.9 per 100,000</p><p class="bulletIndent2"><span class="glyph">•</span>Native American youth – 32.8 per 100,000</p><p class="bulletIndent2"><span class="glyph">•</span>Non-Hispanic Black youth – 37.8 per 100,000</p><p></p><p class="bulletIndent1">There were significant increases in incidence from 2002-2003 through 2014-2015 among all groups except for non-Hispanic White youth, with the greatest adjusted annual increases among Asian/Pacific Islander youth (7.7 percent) and Hispanic youth (6.5 percent) [<a href="#rid3">3</a>]. (See <a class="local">'Risk factors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prediabetes</strong> – In a nationally representative sample in the United States, the overall prevalence of prediabetes in youth 12 to 18 years of age was 18 percent; the prevalence was significantly higher (26 percent) among those with obesity and in males versus females [<a href="#rid12">12</a>]. This study defined prediabetes as an abnormality in fasting plasma glucose (FPG), hemoglobin A1c (A1C), and/or glucose tolerance. The most common abnormality was impaired fasting glucose, present in 11 percent of samples. There was little overlap among the subgroups with abnormal A1C, FPG, or glucose tolerance, indicating that prevalence estimates will vary substantially depending on which of these tests is used. (See <a class="local">'Prediabetes'</a> below.)</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Risk factors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obesity</strong> – Obesity and excess adipose tissue are the most important risk factors for T2DM. Body mass index (BMI) percentiles are used to define overweight and obesity in children and adolescents  (<a class="graphic graphic_table graphicRef78725" href="/z/d/graphic/78725.html" rel="external">table 1</a>). The association between obesity and T2DM is even stronger in youth than in adults [<a href="#rid13">13</a>]. As an example, in a registry study from the United States, nearly 80 percent of youth with T2DM had obesity and an additional 10 percent were overweight [<a href="#rid14">14</a>]. In addition, BMI during adolescence predicts the risk for T2DM during adulthood [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/5869.html" rel="external">"Overview of the health consequences of obesity in children and adolescents", section on 'Type 2 diabetes mellitus'</a>.)</p><p></p><p class="bulletIndent1">The risk for T2DM is associated with an abdominal fat distribution (also called central adiposity, visceral, android, or male-type obesity) [<a href="#rid16">16,17</a>]. Obesity predisposes to T2DM by increasing peripheral resistance to insulin-mediated glucose uptake. (See  <a class="medical medical_review" href="/z/d/html/1771.html" rel="external">"Type 2 diabetes mellitus: Prevalence and risk factors", section on 'Obesity'</a> and  <a class="medical medical_review" href="/z/d/html/1810.html" rel="external">"Pathogenesis of type 2 diabetes mellitus", section on 'Role of diet, obesity, and inflammation'</a>.)</p><p></p><p class="bulletIndent1">Glucose tolerance appears to respond to changes in health behaviors. In one study, a multicomponent intervention aimed at reducing obesity and risk for T2DM in middle school students improved fasting insulin levels (suggesting greater insulin sensitivity) despite minimal effect on overall weight status in the intervention group compared with the control group, although BMI Z-scores were reduced [<a href="#rid18">18</a>]. These benefits were evident in those youth with overweight or obesity at study entry.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic susceptibility</strong> – T2DM is caused by a complex interaction of environmental and genetic factors in susceptible people, based on studies in adults. In the majority of patients with T2DM, genetic susceptibility appears to be due to the expression of multiple genes (ie, the risk is a polygenic trait). (See  <a class="medical medical_review" href="/z/d/html/1810.html" rel="external">"Pathogenesis of type 2 diabetes mellitus", section on 'Genetic susceptibility'</a>.)</p><p></p><p class="bulletIndent1">Evidence for a strong genetic component for T2DM includes the increased risk of T2DM in close relatives of an affected patient:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among monozygotic twins in which one twin has T2DM, the other twin has a 90 percent chance of developing the disease [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children or adolescents with T2DM, one-half to three-quarters have at least one affected parent [<a href="#rid6">6,20,21</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For parents with T2DM, children have an estimated 20 percent risk of developing T2DM by late adulthood (approximately 3.5 times the risk of an individual without parental T2DM) [<a href="#rid22">22</a>]. The risk rises to 30 percent if both parents are affected (approximately six times the risk of an individual with unaffected parents). These figures come from a longitudinal study in a predominantly White population; it is possible that familial risk varies between different racial and ethnic groups.</p><p></p><p class="bulletIndent1">Identification of the relevant genes has been difficult because of the complex inheritance patterns and interactions with the environment [<a href="#rid23">23</a>]. Investigations of genetic susceptibility are ongoing, some of which specifically study patients with early onset of T2DM (under 18 years old). Candidate genes that have been linked to T2DM are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1810.html" rel="external">"Pathogenesis of type 2 diabetes mellitus", section on 'Genetic susceptibility'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ethnicity</strong> – In the United States, T2DM is more common in Native American, African American, Hispanic, Asian American, and Pacific Islander youth than in the general population  (<a class="graphic graphic_figure graphicRef95197" href="/z/d/graphic/95197.html" rel="external">figure 2</a>) [<a href="#rid11">11,20,24-33</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Native American youth – The overall prevalence of T2DM among Native American youth (15 to 19 years) is 4.5 per 1000 [<a href="#rid20">20</a>], with substantial variation among groups:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Pima Indian – 51 per 1000 [<a href="#rid20">20</a>]</p><p class="bulletIndent3"><span class="glyph">-</span>Canadian Cree and Ojibway Indians in Manitoba – 2.3 per 1000 [<a href="#rid20">20</a>]</p><p class="bulletIndent3"><span class="glyph">-</span>Navajo – 2.2 per 1000 [<a href="#rid34">34</a>]</p><p></p><p class="bulletIndent2">The particularly high prevalence among Pima Indian youth may be partly attributable to systematic population screening for this group [<a href="#rid20">20</a>]. The incidence of T2DM among Native American youth is approximately seven times that of non-Hispanic White youth [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Black non-Hispanic youth – Several studies have demonstrated that T2DM disproportionately affects Black non-Hispanic individuals [<a href="#rid11">11,26</a>]. In a registry study in the United States, the prevalence of T2DM among Black non-Hispanic youth was 1.06 per 1000 individuals, five times the rate among White non-Hispanic youth [<a href="#rid11">11</a>]. Similarly, several studies suggest that insulin resistance is greater in Black children compared with White children [<a href="#rid35">35-39</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hispanic youth – Hispanic children also are at increased risk for T2DM compared with the general population. In a registry study in the United States, the prevalence of T2DM among Hispanic youth was 0.79 per 1000 individuals, four times that of White non-Hispanic youth [<a href="#rid11">11</a>]. Hispanic children have been reported to have lower insulin sensitivity [<a href="#rid40">40,41</a>] and reduced pancreatic beta cell function (decreased insulin secretion) [<a href="#rid42">42</a>], both of which increase the risk of diabetes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age and pubertal status</strong> – Many patients with pediatric T2DM present at the onset of or during puberty, a stage of development when there is physiologic insulin resistance [<a href="#rid43">43-45</a>]. Accordingly, virtually all patients recruited for a large trial (TODAY study) were pubertal or postpubertal at study entry [<a href="#rid21">21</a>]. Approximately 40 percent of pediatric cases occur between 10 and 14 years of age, and the remaining 60 percent between 15 and 19 years [<a href="#rid46">46</a>]. During puberty, insulin sensitivity decreases by approximately 30 percent [<a href="#rid47">47</a>], related to the increased activity of growth hormone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sex</strong> – Females are 1.2 to 1.7 times more likely than males to progress from prediabetes and develop T2DM during adolescence [<a href="#rid3">3,11,20,46,48,49</a>]. Although the reason for this increased risk in females is probably multifactorial, it may be related to an increased risk of insulin resistance, as seen in adolescents with polycystic ovary syndrome (PCOS), and could be related to the increase in adiposity versus lean body mass observed in female compared with male adolescents, along with less physical activity in females versus males in late adolescence (albeit based on a study in adolescents with type 1 diabetes mellitus [T1DM]) [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/5799.html" rel="external">"Etiology and pathophysiology of polycystic ovary syndrome in adolescents", section on 'Insulin-resistant hyperinsulinism'</a> and  <a class="medical medical_review" href="/z/d/html/5853.html" rel="external">"Treatment of polycystic ovary syndrome in adolescents", section on 'Treatment of obesity and insulin resistance'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prenatal exposures</strong> – One hypothesis suggests that prenatal exposure to maternal undernutrition or gestational diabetes causes metabolic and hormonal changes in the offspring that promote obesity and insulin resistance and increase the risk for T2DM risk in adulthood. This phenomenon has been termed "metabolic programming."</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Small for gestational age – Low birth weight and/or length for gestational age (a sign of intrauterine undernutrition) is associated with insulin resistance. The combination of low birth weight and weight gain in adult middle age increases insulin resistance and the risk for T2DM  (<a class="graphic graphic_figure graphicRef52859" href="/z/d/graphic/52859.html" rel="external">figure 3</a>) [<a href="#rid51">51</a>]. Individuals with the lowest birth weight and the highest prepubertal body weight appear to be at the greatest risk for insulin resistance and T2DM [<a href="#rid52">52-54</a>]. (See  <a class="medical medical_review" href="/z/d/html/1810.html" rel="external">"Pathogenesis of type 2 diabetes mellitus", section on 'Role of intrauterine development'</a> and  <a class="medical medical_review" href="/z/d/html/5062.html" rel="external">"Infants with fetal (intrauterine) growth restriction"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gestational diabetes – The abnormal intrauterine metabolic environment of a pregnancy complicated by diabetes appears to increase the risk of T2DM. Intrauterine exposure to hyperglycemia and hyperinsulinemia may affect the development of adipose tissue and pancreatic beta cells, leading to future obesity and altered glucose metabolism. In the SEARCH for Diabetes in Youth study, gestational or pre-gestational diabetes and intrauterine exposure to maternal obesity were independently associated with T2DM in adolescents, and both risk factors were present in 47 percent of the SEARCH cohort [<a href="#rid55">55</a>]. The effects of gestational diabetes on the risk of developing T2DM in the offspring are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5058.html" rel="external">"Infants of mothers with diabetes (IMD)", section on 'Diabetes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PCOS</strong> – Insulin resistance is a component of PCOS and may play a role in its pathogenesis. Patients with PCOS are at increased risk for developing T2DM. (See  <a class="medical medical_review" href="/z/d/html/94182.html" rel="external">"Diagnostic evaluation of polycystic ovary syndrome in adolescents", section on 'Additional evaluation of PCOS patients'</a> and  <a class="medical medical_review" href="/z/d/html/5799.html" rel="external">"Etiology and pathophysiology of polycystic ovary syndrome in adolescents", section on 'Insulin-resistant hyperinsulinism'</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The presentation of T2DM in children and adolescents is variable, ranging from incidental detection to symptoms of hyperglycemia, diabetic ketoacidosis (DKA), or hyperosmolar hyperglycemia [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H11215830"><span class="h2">Asymptomatic</span><span class="headingEndMark"> — </span>Approximately 40 percent of children and adolescents with T2DM are identified while asymptomatic [<a href="#rid26">26,57</a>]. These patients may be tested for T2DM because of risk factors or because glycosuria was detected on a urinalysis obtained as part of a routine physical examination [<a href="#rid48">48</a>]. (See <a class="local">'Screening'</a> below.)</p><p class="headingAnchor" id="H11215897"><span class="h2">Common symptoms</span><span class="headingEndMark"> — </span>Approximately 60 percent of children and adolescents with T2DM are symptomatic at presentation [<a href="#rid26">26,57</a>]. The main symptoms are due to hyperglycemia and commonly include polyuria, polydipsia, and nocturia, similar to those in patients with type 1 diabetes mellitus (T1DM). Symptomatic patients also may have experienced recent weight loss, although this is not a common presenting complaint, and the percentage of weight loss is typically less than in patients with T1DM [<a href="#rid48">48,49</a>].</p><p>Occasionally, the presenting complaint may be vaginal discharge or <em>Candida</em> vulvovaginitis in females (typical symptoms are pruritus or burning) or tinea cruris in adolescent males [<a href="#rid48">48,58</a>]. (See  <a class="medical medical_review" href="/z/d/html/5452.html" rel="external">"Candida vulvovaginitis: Clinical manifestations and diagnosis", section on 'Risk factors'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Diabetic ketoacidosis</span><span class="headingEndMark"> — </span>Occasionally, children with T2DM present with DKA (hyperglycemia, ketonuria, and acidosis). Symptoms are due to hyperglycemia and include polyuria (due to the glucose osmotic diuresis), polydipsia (due to increased urinary losses), fatigue, and lethargy. Children with DKA require hospitalization, rehydration, and insulin replacement therapy. (See  <a class="medical medical_review" href="/z/d/html/5809.html" rel="external">"Diabetic ketoacidosis in children: Clinical features and diagnosis", section on 'Signs and symptoms'</a> and  <a class="medical medical_review" href="/z/d/html/5808.html" rel="external">"Diabetic ketoacidosis in children: Treatment and complications"</a>.)</p><p>The reported frequency of DKA as the initial presentation for childhood T2DM varies from 5 to 12 percent depending on the population studied [<a href="#rid26">26,59-61</a>], with further increases during the coronavirus disease 2019 (COVID-19) pandemic [<a href="#rid62">62-64</a>]. Presentation with DKA appears to be most common in Black or African American youth, among whom up to 25 percent present with DKA [<a href="#rid49">49,65</a>]. In a case series that included 28 non-Hispanic Black patients with T2DM, 25 percent presented with DKA and an additional 43 percent presented with ketonuria but without acidosis [<a href="#rid65">65</a>]. In contrast, none of the 12 White patients in the same study had ketonuria or DKA. In an observational study of 21 Mexican American children with newly diagnosed T2DM, approximately one-third had ketonuria [<a href="#rid66">66</a>].</p><p>Nonetheless, most patients who first present with DKA have T1DM rather than T2DM: among more than 1500 youth presenting with DKA, approximately 95 percent had T1DM and 5 percent had T2DM [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/z/d/html/5809.html" rel="external">"Diabetic ketoacidosis in children: Clinical features and diagnosis", section on 'Epidemiology'</a> and <a class="local">'Type 2 versus type 1 diabetes'</a> below.)</p><p class="headingAnchor" id="H13"><span class="h2">Hyperosmolar hyperglycemic state</span><span class="headingEndMark"> — </span>Rarely, adolescents with T2DM may present with hyperosmolar hyperglycemic state (HHS), also referred to as hyperosmolar hyperglycemic nonketotic syndrome (HHNK) [<a href="#rid68">68-72</a>]. This condition is a medical emergency; it is characterized by [<a href="#rid68">68</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Marked hyperglycemia (plasma glucose &gt;600 mg/dL)</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperosmolality (serum osmolality &gt;330 mOsm/kg)</p><p class="bulletIndent1"><span class="glyph">●</span>Severe dehydration</p><p class="bulletIndent1"><span class="glyph">●</span>Little or no ketonuria</p><p></p><p>Initially described in adult patients with poorly controlled T2DM, the condition has also been reported in adolescents, most of whom were African American with newly diagnosed T2DM [<a href="#rid69">69-74</a>]. In one report, HHS was the presenting feature of T2DM in approximately 2 percent of adolescents [<a href="#rid59">59</a>]. Recognition of HHS is important because it is characterized by more severe dehydration than typical DKA and has high morbidity and mortality if not adequately treated. Management of HHS is discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/1795.html" rel="external">"Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment", section on 'Fluid replacement'</a>.)</p><p class="headingAnchor" id="H836809417"><span class="h1">SCREENING</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – For asymptomatic children and adolescents we use the following criteria for initial screening for T2DM  (<a class="graphic graphic_table graphicRef56279" href="/z/d/graphic/56279.html" rel="external">table 2</a>), consistent with recommendations from the American Diabetes Association and International Society for Pediatric and Adolescent Diabetes [<a href="#rid75">75-77</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Overweight or obesity (body mass index [BMI] ≥85<sup>th</sup> percentile) <strong>and</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One or more of the following additional risk factors:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>T2DM in a first- or second-degree relative</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Member of a high-risk racial/ethnic group: Native American, African American, Latino, Asian/Pacific Islander, Canadian First Nations, Australian indigenous</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>History of maternal diabetes or gestational diabetes during the child's gestation</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Signs of insulin resistance or conditions associated with insulin resistance (eg, acanthosis nigricans, hypertension, dyslipidemia, polycystic ovary syndrome [PCOS], or small for gestational age birth weight and/or length)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Current use of weight-promoting atypical antipsychotic drug [<a href="#rid77">77</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Method</strong> – Screening should begin at the onset of puberty or ≥10 years (whichever is earlier). We use hemoglobin A1c (A1C) and/or fasting plasma glucose (FPG) to screen for T2DM in asymptomatic adolescents. Patients with abnormal results require further evaluation. (See <a class="local">'Asymptomatic with abnormal screening results'</a> below.)</p><p></p><p class="bulletIndent1">We repeat the screening approximately annually in patients with marked obesity or strong evidence of insulin resistance (eg, acanthosis nigricans), or in patients with borderline results. This is consistent with the American Diabetes Association recommendations to repeat screening at a minimum of every three years or more frequently if BMI is increasing [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence</strong> – In adolescents, targeted testing of risk groups has a low yield for identifying T2DM but a high yield for identifying patients with prediabetes. As an example, one study that tested a population of 8<sup>th</sup> grade students in the United States found T2DM in 0.5 percent, while 43 percent met criteria for prediabetes [<a href="#rid41">41</a>]. Most of the subjects had multiple risk factors for T2DM, including high-risk race/ethnicity. Estimates of prediabetes prevalence vary substantially among studies, depending on the risk factors in the population and the tests used for the evaluation.</p><p></p><p class="bulletIndent1">No studies in children have examined whether early diagnosis improves the long-term outcome of T2DM. However, indirect evidence suggests that identifying individuals with prediabetes may be valuable because studies in adults indicate that lifestyle intervention can prevent or delay the onset of T2DM [<a href="#rid79">79</a>]. For these reasons, targeted testing of adolescents with multiple risk factors for T2DM is recommended, as outlined below.</p><p></p><p class="headingAnchor" id="H21"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H1496219521"><span class="h2">Asymptomatic with abnormal screening results</span><span class="headingEndMark"> — </span>For asymptomatic children with abnormal screening results, the next step depends upon the level of concern:</p><p class="bulletIndent1"><span class="glyph">●</span>For those with laboratory abnormalities in the prediabetes range  (<a class="graphic graphic_table graphicRef82479" href="/z/d/graphic/82479.html" rel="external">table 3</a>), it is reasonable to repeat the screening test in three to six months. If there is a high clinical suspicion of diabetes (eg, severe obesity and/or multiple risk factors for diabetes  (<a class="graphic graphic_table graphicRef56279" href="/z/d/graphic/56279.html" rel="external">table 2</a>)), repeat the screening test (eg, hemoglobin A1c [A1C]) sooner and/or proceed to an oral glucose tolerance test (OGTT).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those with more severe abnormalities (eg, A1C ≥6.5 percent), repeat the A1C and/or at least one additional laboratory test for diabetes and perform a urinalysis. (See <a class="local">'Laboratory tests'</a> below.)</p><p></p><p class="headingAnchor" id="H4192313951"><span class="h2">Symptomatic</span><span class="headingEndMark"> — </span>All patients with symptoms suggesting possible diabetes (polydipsia, polyuria, blurred vision, unexplained weight loss) should be tested for diabetes, regardless of risk factors. (See <a class="local">'Clinical presentation'</a> above.)</p><p>The usual first step for symptomatic patients is to measure random plasma glucose, A1C, and urinalysis to evaluate for glucosuria and/or ketonuria. (See <a class="local">'Laboratory tests'</a> below and <a class="local">'Diagnosis'</a> below.)</p><p class="headingAnchor" id="H23"><span class="h2">Laboratory tests</span><span class="headingEndMark"> — </span>Testing for diabetes can be done by measuring A1C or fasting plasma glucose (FPG) or by performing an OGTT [<a href="#rid75">75</a>]. In our practice, we measure either FPG or A1C and confirm abnormal results by either repeating the initial test on another day or by performing a different test. A1C should be included at least once to provide a baseline and is often repeated for confirmation of the diagnosis in patients without symptoms.</p><p>The characteristics of each of these laboratory tests are outlined below, and diagnostic criteria for prediabetes and diabetes are summarized in the tables  (<a class="graphic graphic_table graphicRef82479" href="/z/d/graphic/82479.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef61853" href="/z/d/graphic/61853.html" rel="external">table 4</a>). (See <a class="local">'Diagnosis'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Random (nonfasting) plasma glucose</strong> — The primary indication for a random plasma glucose is for urgent evaluation of a patient with symptoms suggesting hyperglycemia (eg, polydipsia, polyuria, blurred vision, unexplained weight loss). Results are interpreted as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Normal – Random plasma glucose &lt;140 mg/dL (&lt;7.8 mmol/L) suggests that the current symptoms may not be related to hyperglycemia but does not entirely exclude the possibility of diabetes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Moderately elevated – Random plasma glucose 140 to 199 mg/dL (7.8 to 11 mmol/L) is concerning for impaired glucose tolerance and should be followed by the other tests below for more accurate evaluation of glycemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Elevated – Random plasma glucose ≥200 mg/dL (11.1 mmol/L) in a patient with classic symptoms of hyperglycemia is diagnostic of diabetes.</p><p></p><p class="bulletIndent1">These glucose measurements should be obtained in a clinical laboratory and not based solely on a point-of-care glucose meter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>A1C</strong> – A1C (glycated hemoglobin) is accepted as a screening test for diabetes mellitus. It is useful in clinical practice because it does not require fasting, but its performance as a screening test has not been fully validated in adolescents. Diagnostic criteria using A1C for adult and pediatric patients are [<a href="#rid77">77,78,80</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diabetes – A1C level ≥6.5 percent (48 mmol/mol), on two occasions </p><p class="bulletIndent2"><span class="glyph">•</span>Prediabetes – A1C level between 5.7 and 6.4 percent</p><p></p><p class="bulletIndent1">Use of A1C as a screening test was supported by an international consensus statement and endorsed by the American Diabetes Association, provided that the A1C assay is certified by the National Glycohemoglobin Standardization Program and performed in a certified laboratory and not by using a point-of-care device [<a href="#rid78">78,81</a>]. Although some point-of-care A1C devices are certified for glycemic monitoring, most are not appropriate for initial screening and diagnosis of diabetes. Although traditionally reported as a percent, A1C is increasingly reported as mmol/mol (<a class="calc calc_professional" href="/z/d/html/15628.html" rel="external">calculator 1</a>). (See  <a class="medical medical_review" href="/z/d/html/1812.html" rel="external">"Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults", section on 'A1C'</a>.)</p><p></p><p class="bulletIndent1">Although A1C may be used for screening in adolescents, the results should be interpreted with some caution because A1C has not been well validated as a screening test in this population [<a href="#rid75">75</a>]. Almost all of the data on A1C as a screening test are based on studies in adults. One study in a population-based sample of adolescents concluded that a single measurement of A1C ≥6.5 percent had modest specificity (75 to 76 percent) and sensitivity (86 to 91 percent) for detecting undiagnosed diabetes mellitus [<a href="#rid82">82</a>]. These findings should be interpreted with caution because they are based on only five cases of undiagnosed T2DM in a sample of 14,119 youth. An earlier study with similar design estimated specificity and sensitivity of 99 and 75 percent, respectively [<a href="#rid83">83</a>]. These observations suggest that an elevated A1C (on two occasions, using a certified laboratory assay) can be used to diagnose diabetes, but a normal A1C does not exclude T2DM.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>FPG</strong> – Compared with the OGTT, FPG is more convenient, less expensive, and less invasive but also less sensitive [<a href="#rid41">41</a>]. Diagnostic criteria using FPG for adult and pediatric patients are [<a href="#rid78">78</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diabetes – FPG ≥126 mg/dL (7.0 mmol/L), if confirmed by another test on a different day (or if classic symptoms of diabetes are present)</p><p class="bulletIndent2"><span class="glyph">•</span>Prediabetes – FPG ≥100 mg/dL to 125 mg/dL (≥5.6 mmol/L to 6.9 mmol/L)</p><p></p><p class="bulletIndent1">These glucose measurements should be performed in a clinical laboratory and not based solely on a point-of-care glucose meter.</p><p></p><p class="bulletIndent1">Children with FPG values in the upper one-half of the normal range (between 86 and 99 mg/dL) have 2.1 times the risk for developing diabetes during adulthood and 3.4 times the risk for developing prediabetes, independent of the child's weight status [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>OGTT</strong> – The OGTT is helpful when there is a need for more accurate evaluation of dysglycemia, such as when the clinical suspicion for diabetes remains high despite an FPG or A1C that is nondiagnostic.</p><p></p><p class="bulletIndent1">The standard glucose load used for the OGTT in children is 1.75 g/kg, up to a maximum dose of 75 g. Results are interpreted as follows [<a href="#rid78">78</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diabetes – Plasma glucose ≥200 mg/dL (11.1 mmol/L) measured two hours after the glucose load</p><p class="bulletIndent2"><span class="glyph">•</span>Prediabetes – Plasma glucose ≥140 to 199 mg/dL (≥7.8 to 11.0 mmol/L) measured two hours after the glucose load</p><p></p><p class="bulletIndent1">The OGTT is a more sensitive test than FPG because OGTT detects patients with diabetes early in the development of their disease when the FPG may not be elevated [<a href="#rid85">85</a>]. Evidence from adult patients with diabetes shows that approximately 30 percent of individuals will have a nondiabetic fasting glucose concentration when their OGTT is diagnostic for diabetes [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1">There are several limitations to the use of the OGTT in children and adolescents. First, it is unknown whether the diagnostic cut points used for adults are applicable to children. Furthermore, the available evidence to support the glucose dose used for children (1.75 g/kg; maximum dose 75 g) is not strong and its validity has been challenged [<a href="#rid23">23</a>]. Finally, there is some evidence that the OGTT may be less reliable in children than in adults. One study has shown poor reproducibility of results in 60 obese children who had two OGTTs performed 1 to 25 days apart [<a href="#rid87">87</a>]. Performing an OGTT in patients currently treated with <a class="drug drug_pediatric" data-topicid="12589" href="/z/d/drug information/12589.html" rel="external">metformin</a> may mask the diagnosis of diabetes, suggesting the need for a one- to two-week washout period off of metformin before performing the OGTT [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tests for ketoacidosis</strong> – Evaluate for diabetic ketoacidosis (DKA) as soon as diabetes is confirmed or strongly suspected, because 5 to 10 percent of adolescents with T2DM present with DKA. If the patient is asymptomatic, measuring serum bicarbonate and urinary ketones is sufficient. If the results are abnormal or if the patient is symptomatic (polydipsia, polyuria, or signs of dehydration), measure venous pH and serum beta-hydroxybutyrate (or urinary ketones). (See <a class="local">'Diabetic ketoacidosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tests to distinguish type 1 diabetes mellitus (T1DM) from T2DM</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pancreatic autoantibodies</strong> – As soon as diabetes is confirmed, test all patients with a panel of pancreatic (islet) autoantibodies even if the patient has a classic presentation of T2DM [<a href="#rid76">76,77</a>]. The panel should include anti-glutamic acid decarboxylase (GAD) and tyrosine phosphatase insulinoma-associated antigen 2 (IA2) antibodies. Insulin autoantibodies (IAA) should be included provided that insulin replacement therapy has not yet been initiated or has been used for less than two weeks. Testing for a beta cell-specific autoantibody to zinc transporter 8 (ZnT8) is also valuable and is becoming more widely available [<a href="#rid89">89</a>]. (See <a class="local">'Type 2 versus type 1 diabetes'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>C-peptide</strong> – If the diabetes type remains uncertain, a C-peptide level (and/or a serum insulin level if insulin therapy has not yet been initiated) obtained after glycemic control has been established may also provide clinically useful information. A low C-peptide level supports a diagnosis of T1DM but should be interpreted with caution because this can also be low at the time of diagnosis of T2DM [<a href="#rid90">90</a>].</p><p></p><p class="headingAnchor" id="H11216200"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H1808045442"><span class="h2">Prediabetes</span><span class="headingEndMark"> — </span>Prediabetes refers to a state of increased risk for future development of diabetes, and is typically defined by any of the following  (<a class="graphic graphic_table graphicRef82479" href="/z/d/graphic/82479.html" rel="external">table 3</a>) [<a href="#rid75">75</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin A1c (A1C) 5.7 to 6.4 percent (39 to 47 mmol/mol)</p><p class="bulletIndent1"><span class="glyph">●</span>Fasting plasma glucose (FPG) 100 to 125 mg/dL (5.6 to 6.9 mmol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Oral glucose tolerance test (OGTT) with plasma glucose 140 to 199 mg/dL (7.8 to 11.0 mmol/L) two hours after a glucose load</p><p></p><p class="bulletIndent1">For adolescents with A1C or FPG results consistent with prediabetes, or with discordant results for either of these tests, we suggest further testing with an OGTT, especially in patients with multiple risk factors for T2DM, because OGTT is more sensitive than A1C and FPG. Subsequent management is discussed below. (See <a class="local">'Subsequent management'</a> below.)</p><p></p><p class="headingAnchor" id="H14731595"><span class="h2">Diabetes mellitus</span><span class="headingEndMark"> — </span>The first step is to diagnose diabetes; the second step is to differentiate T2DM from other types of diabetes. (See <a class="local">'Type 2 versus type 1 diabetes'</a> below and <a class="local">'Other causes of diabetes'</a> below.)</p><p>Diabetes mellitus is diagnosed based upon any one of following  (<a class="graphic graphic_table graphicRef61853" href="/z/d/graphic/61853.html" rel="external">table 4</a>) [<a href="#rid77">77,78</a>]: (See <a class="local">'Laboratory tests'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>A1C ≥6.5 percent (48 mmol/mol)</p><p class="bulletIndent1"><span class="glyph">●</span>FPG ≥126 mg/dL (7 mmol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Random plasma glucose ≥200 mg/dL (11.1 mmol/L) in a patient with classic symptoms of hyperglycemia</p><p class="bulletIndent1"><span class="glyph">●</span>OGTT with plasma glucose ≥200 mg/dL (11.1 mmol/L) two hours after a glucose load</p><p></p><p>Unless unequivocal symptomatic hyperglycemia is present, the diagnosis should be confirmed by repeat testing on a different day. Hyperglycemia that is associated with acute stress (eg, acute infection or surgery) is not diagnostic of diabetes; it should be treated but may be transient. These diagnostic criteria are the same as those used in adults. (See  <a class="medical medical_review" href="/z/d/html/1812.html" rel="external">"Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults"</a>.)</p><p>Glucosuria is suggestive of diabetes but not diagnostic. For example, patients with renal glucosuria or Fanconi syndrome present with glycosuria but will be normoglycemic.</p><p>Severe hyperglycemia (plasma glucose ≥600 mg/dL [33 mmol/L]) suggests the possibility of hyperosmolar hyperglycemic state (HHS), which is a medical emergency. (See <a class="local">'Hyperosmolar hyperglycemic state'</a> above.)</p><p class="headingAnchor" id="H3455112903"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="headingAnchor" id="H11216221"><span class="h2">Type 2 versus type 1 diabetes</span><span class="headingEndMark"> — </span>It is important to distinguish between T2DM versus type 1 diabetes mellitus (T1DM), because management differs. T2DM is characterized by hyperglycemia, insulin resistance, and relative impairment in insulin secretion. By contrast, the primary characteristic of T1DM is absolute insulin deficiency, which usually is caused by immune-mediated destruction of pancreatic beta cells, as indicated by the presence of autoantibodies. Insulin resistance can also be present in T1DM [<a href="#rid91">91</a>]. At the time of presentation, it may be difficult to distinguish between T1DM and T2DM. The presence of pancreatic autoantibodies, however, is considered diagnostic of T1DM. (See <a class="local">'Pathogenesis'</a> above.)</p><p>No set of criteria or diagnostic test can consistently distinguish between T1DM and T2DM. Therefore, differentiating between the two types is based upon a combination of the clinical presentation and history, often supported by laboratory studies  (<a class="graphic graphic_table graphicRef59370" href="/z/d/graphic/59370.html" rel="external">table 5</a>) (see  <a class="medical medical_review" href="/z/d/html/5816.html" rel="external">"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical characteristics</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Body habitus – Patients with T2DM are usually obese (body mass index [BMI] ≥95<sup>th</sup> percentile for age and sex). In contrast, children with T1DM are often not overweight and usually have a recent history of weight loss, although 25 percent or more may have overweight or obesity (BMI ≥85<sup>th</sup>) at diagnosis [<a href="#rid14">14,92,93</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age – Youth with T2DM generally present after the onset of puberty, and almost all present after 10 years of age  (<a class="graphic graphic_figure graphicRef88297" href="/z/d/graphic/88297.html" rel="external">figure 4</a>) [<a href="#rid46">46</a>]. By contrast, approximately 50 percent of youth with T1DM present prior to 10 years of age [<a href="#rid94">94</a>]. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Insulin resistance – Patients with T2DM usually have clinical features associated with insulin resistance such as acanthosis nigricans, hypertension, dyslipidemia, and polycystic ovary syndrome (PCOS), which are not commonly seen in children with T1DM. As an example, in studies in the United States, 50 to 90 percent of youth diagnosed with T2DM have acanthosis nigricans [<a href="#rid20">20,91</a>]. Among those clinically diagnosed with T1DM, up to 25 percent have biochemical evidence of insulin resistance and approximately 12 percent have acanthosis nigricans [<a href="#rid91">91</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Family history – 75 to 90 percent of those with T2DM have an affected first- or second-degree relative, whereas only up to 10 percent of patients with T1DM have an affected first- or second-degree relative. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ethnicity – In the United States, most pediatric patients with T2DM belong to certain racial and ethnic groups including non-Hispanic Black, Hispanic, Native American, Asian American, and Pacific Islander youth, although either type of diabetes can occur in any of these racial or ethnic groups. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory results</strong> (see <a class="local">'Laboratory tests'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ketoacidosis – The presence of diabetic ketoacidosis (DKA) supports a diagnosis of T1DM, but does not exclude T2DM. DKA is present at diagnosis in approximately 30 percent of children with T1DM, compared with 5 to 10 percent of those with T2DM. (See <a class="local">'Diabetic ketoacidosis'</a> above and  <a class="medical medical_review" href="/z/d/html/5809.html" rel="external">"Diabetic ketoacidosis in children: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pancreatic autoantibodies – The presence of pancreatic autoantibodies (glutamic acid decarboxylase [GAD], tyrosine phosphatase insulinoma-associated antigen 2 [IA2], insulin autoantibodies [IAA], or zinc transporter antibodies [ZnT8]) supports a diagnosis of T1DM. However, up to 10 percent of adolescents with T2DM diagnosed on the basis of clinical phenotype have evidence of beta cell autoimmunity [<a href="#rid90">90</a>]. Thus, the pathophysiologic features of both types of diabetes may coexist in the same patient, particularly if the patient has overweight or obesity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Insulin and C-peptide levels – A C-peptide level (and/or a serum insulin level if insulin therapy has not yet been initiated) obtained after glycemic control has been established may also provide clinically useful information. Low C-peptide levels support a diagnosis of T1DM but should be interpreted with caution because they can also be low at the time of diagnosis of T2DM. Fasting serum insulin and C-peptide levels have not been standardized to distinguish between type 1 and 2 diabetes [<a href="#rid95">95,96</a>].</p><p></p><p class="bulletIndent1">Some patients may have mixed features and are difficult to classify. As an example, some patients with features suggesting T2DM also have atypical characteristics, such as presenting with ketosis ("ketosis-prone T2DM") or ketoacidosis, and/or the presence of pancreatic autoantibodies. The challenges of categorizing types of diabetes were illustrated in a multicenter study in which pediatric diabetes was classified based upon the presence or absence of beta cell autoimmunity and the presence or absence of insulin sensitivity [<a href="#rid91">91</a>]. More than 70 percent of patients fell into traditional categories of autoimmune and insulin-sensitive T1DM (55 percent) or nonautoimmune and insulin-resistant T2DM (16 percent). An additional 20 percent had both autoimmunity and insulin resistance, a pattern typical for obese patients with T1DM. The remaining 10 percent of patients were insulin sensitive in the absence of pancreatic autoimmunity, most of whom were clinically categorized as T1DM (ie, type 1B diabetes) and the remainder as T2DM. Of these 10 percent of patients with insulin sensitivity and without markers of pancreatic autoimmunity, nearly 10 percent (or approximately 1 percent of the entire study cohort) had evidence of a genetic basis for their diabetes [<a href="#rid96">96</a>]. (See <a class="local">'Other causes of diabetes'</a> below.)</p><p></p><p class="bulletIndent1">In these patients with atypical features, evaluation for other forms of diabetes (eg, monogenic diabetes) should be considered, as discussed in the next section. (See  <a class="medical medical_review" href="/z/d/html/1793.html" rel="external">"Classification of diabetes mellitus and genetic diabetic syndromes", section on 'Distinguishing type 1 from type 2 diabetes'</a> and <a class="local">'Other causes of diabetes'</a> below.)</p><p></p><p class="headingAnchor" id="H11216228"><span class="h2">Other causes of diabetes</span><span class="headingEndMark"> — </span>Other forms of diabetes should be considered in patients with atypical features, mixed features of T2DM and T1DM, or underlying diseases. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Monogenic diabetes – Consider monogenic diabetes in patients with a multigenerational family history of early-onset diabetes (eg, across three or more generations), clinical features of T2DM, positive C-peptide, and negative pancreatic autoantibodies (especially in patients without overweight or obesity) [<a href="#rid96">96-98</a>]. (See  <a class="medical medical_review" href="/z/d/html/1793.html" rel="external">"Classification of diabetes mellitus and genetic diabetic syndromes", section on 'Monogenic diabetes (formerly called maturity onset diabetes of the young)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diseases of the exocrine system – Cystic fibrosis, hereditary hemochromatosis, and chronic pancreatitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endocrine abnormalities in glucose regulation – Cushing syndrome, glucagon-secreting tumors, catecholamine excess in pheochromocytoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug-induced diabetes – eg, glucocorticoids, HIV protease inhibitors and others  (<a class="graphic graphic_table graphicRef67257" href="/z/d/graphic/67257.html" rel="external">table 6</a>).</p><p></p><p>These diseases are discussed in greater detail separately; see appropriate topic reviews and (see  <a class="medical medical_review" href="/z/d/html/5816.html" rel="external">"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents", section on 'Other causes of diabetes'</a> and  <a class="medical medical_review" href="/z/d/html/1793.html" rel="external">"Classification of diabetes mellitus and genetic diabetic syndromes"</a>)</p><p class="headingAnchor" id="H907348028"><span class="h1">SUBSEQUENT MANAGEMENT</span></p><p class="headingAnchor" id="H2448430318"><span class="h2">Patients with prediabetes</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Laboratory screening for T2DM should be repeated annually unless there is a change in symptoms or signs (eg, weight change or polydipsia/polyuria) that indicates a need for earlier retesting. (See <a class="local">'Prediabetes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weight management</strong> – Patients with prediabetes should be engaged in intensive lifestyle interventions similar to the nonpharmacologic therapy recommended for patients with established T2DM. For most such patients, weight reduction is an important goal.</p><p></p><p class="bulletIndent1">Studies in adults suggest that intensive lifestyle interventions in patients with prediabetes can prevent or delay the onset of T2DM [<a href="#rid99">99</a>]. The natural history of prediabetes in adolescents is not well described. In a cohort of 526 adolescents with obesity and impaired glucose tolerance seen in a pediatric obesity clinic, 8 percent progressed to T2DM with median duration of follow-up of 2.9 years and 65 percent reverted to normal glucose tolerance [<a href="#rid100">100</a>]. The risk of progression to T2DM was markedly higher for non-Hispanic Black adolescents compared with White adolescents. Thus, estimates of progression vary depending on ethnicity, obesity, and other risk factors, as well as the test used to determine prediabetes. (See  <a class="medical medical_review" href="/z/d/html/5821.html" rel="external">"Management of type 2 diabetes mellitus in children and adolescents", section on 'Nonpharmacologic therapy'</a>.)</p><p></p><p class="bulletIndent1">For adolescents with severe obesity, weight loss surgery results in durable weight loss and improvements in dysglycemia and other comorbidities. (See  <a class="medical medical_review" href="/z/d/html/5880.html" rel="external">"Surgical management of severe obesity in adolescents", section on 'Comorbidity improvement'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of medications</strong> – It is unclear whether <a class="drug drug_pediatric" data-topicid="12589" href="/z/d/drug information/12589.html" rel="external">metformin</a> is beneficial for adolescents with prediabetes or with other evidence of insulin resistance. Available data from a few trials suggest that treatment with metformin improves markers of insulin sensitivity and slightly reduces body mass index (BMI) [<a href="#rid101">101-103</a>]. However, the improvements are modest, and there is no evidence that metformin alters long-term risks for developing prediabetes or diabetes.</p><p></p><p class="bulletIndent1">In the Restoring Insulin Secretion (RISE) pediatric medication study, treatment with <a class="drug drug_pediatric" data-topicid="12589" href="/z/d/drug information/12589.html" rel="external">metformin</a> for 12 months, or <a class="drug drug_pediatric" data-topicid="12633" href="/z/d/drug information/12633.html" rel="external">insulin glargine</a> for three months followed by metformin for nine months, failed to prevent deterioration of beta cell function at 12 months and upon retesting at 15 months [<a href="#rid104">104</a>]. In the subgroup with prediabetes (impaired glucose tolerance) at baseline, 6 percent (3 of 54 patients) progressed to T2DM at 15 months despite the medications. Among subjects with prediabetes or early diabetes, the adolescents showed greater insulin resistance and a concomitant increase in beta cell function to compensate for the insulin-resistant state, and a more rapid decline in beta cell function over time compared with adults [<a href="#rid105">105,106</a>].</p><p></p><p class="bulletIndent1">By contrast, studies in adults with prediabetes suggest that similar treatments improve insulin secretion and preserved glycemic control [<a href="#rid107">107,108</a>]. (See  <a class="medical medical_review" href="/z/d/html/1774.html" rel="external">"Prevention of type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1">These studies do not exclude the possibility of some protective effect of medication in pediatric subjects with prediabetes, because there was no placebo-treated group for comparison. However, they indicate a need for more aggressive approaches for the management of prediabetes in youth, including lifestyle management and the possible addition of medications that require further study.</p><p></p><p class="headingAnchor" id="H1674831737"><span class="h2">Patients with diabetes</span><span class="headingEndMark"> — </span>Management of patients with T2DM is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5821.html" rel="external">"Management of type 2 diabetes mellitus in children and adolescents"</a>.)</p><p class="headingAnchor" id="H3489267758"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111575.html" rel="external">"Society guideline links: Diabetes mellitus in children"</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – The risk of type 2 diabetes mellitus (T2DM) is increased in children and adolescents who are overweight or obese  (<a class="graphic graphic_table graphicRef78725" href="/z/d/graphic/78725.html" rel="external">table 1</a>), have an affected close relative, or are a member of a high-risk racial/ethnic group (eg, Non-Hispanic Black, Native American, Hispanic, Pacific Islander, and Asian American). Because puberty increases insulin resistance, most cases of childhood T2DM occur after the onset of puberty, which is a time of physiologic insulin resistance. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – A majority of children and adolescents with T2DM have some symptoms of hyperglycemia, including polyuria, polydipsia, fatigue, and lethargy at presentation. A minority of T2DM patients present with diabetic ketoacidosis (DKA). Approximately 40 percent of patients are asymptomatic at the time of diagnosis and are identified by testing for the disease because of risk factors or by urinalysis obtained during routine care. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong> – All children should be assessed for risk factors for T2DM (eg, obesity, family history, high-risk racial/ethnic group  (<a class="graphic graphic_table graphicRef56279" href="/z/d/graphic/56279.html" rel="external">table 2</a>)) at routine well-child visits. For children who are overweight or obese and have one or more additional risk factor for T2DM, we suggest laboratory screening (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Screening consists of either fasting plasma glucose (FPG) or hemoglobin A1c (A1C). It is typically performed every three years beginning at 10 years of age or at the onset of puberty (whichever occurs first); it's performed more frequently in patients with marked obesity or strong evidence of insulin resistance (eg, acanthosis nigricans) or in patients with borderline results. (See <a class="local">'Screening'</a> above and <a class="local">'Laboratory tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Abnormal screening results</strong> – For asymptomatic children with abnormal screening results, the next step depends upon the level of concern. For those with abnormalities in the prediabetes range  (<a class="graphic graphic_table graphicRef82479" href="/z/d/graphic/82479.html" rel="external">table 3</a>), it is reasonable to repeat the screening test in three to six months. If there is a high clinical suspicion of diabetes (eg, severe obesity and/or multiple risk factors for diabetes  (<a class="graphic graphic_table graphicRef56279" href="/z/d/graphic/56279.html" rel="external">table 2</a>)), repeat the screening test (eg, A1C) sooner (ie, within three months) and/or proceed to an oral glucose tolerance test (OGTT). (See <a class="local">'Asymptomatic with abnormal screening results'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Symptomatic patients</strong> – All patients with symptoms suggesting possible diabetes (polydipsia, polyuria, blurred vision, unexplained weight loss) should be tested for diabetes, regardless of risk factors. The first step for symptomatic patients is typically a random plasma glucose and A1C. If these are not diagnostic for diabetes, measure FPG and repeat A1C. An OGTT should be performed if the initial tests are equivocal and there is need for more accurate evaluation of dysglycemia. (See <a class="local">'Symptomatic'</a> above and <a class="local">'Laboratory tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis and initial management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prediabetes</strong> – Prediabetes refers to a state of increased risk for future development of diabetes and is defined by mild abnormalities in FPG, A1C, or glucose tolerance  (<a class="graphic graphic_table graphicRef82479" href="/z/d/graphic/82479.html" rel="external">table 3</a>). Adolescents with laboratory abnormalities in this range should undergo focused lifestyle intervention to support weight loss and should be rescreened for T2DM at least annually. Youth with prediabetes or early T2DM generally experience progressive deterioration of beta cell function. (See <a class="local">'Prediabetes'</a> above and <a class="local">'Subsequent management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diabetes</strong> – The diagnosis of diabetes is based upon the detection of one of four abnormalities of glucose metabolism; confirmatory testing is required unless symptoms are present  (<a class="graphic graphic_table graphicRef61853" href="/z/d/graphic/61853.html" rel="external">table 4</a>). (See <a class="local">'Diabetes mellitus'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A1C ≥6.5 percent (48 mmol/mol) on a laboratory assay (not point-of-care A1C testing)</p><p class="bulletIndent3"><span class="glyph">-</span>FPG ≥126 mg/dL (7 mmol/L)</p><p class="bulletIndent3"><span class="glyph">-</span>Symptoms of hyperglycemia and a random plasma glucose ≥200 mg/dL (11.1 mmol/L)</p><p class="bulletIndent3"><span class="glyph">-</span>Plasma glucose ≥200 mg/dL (11.1 mmol/L) measured two hours after a glucose load in an OGTT</p><p></p><p class="bulletIndent2">Management of T2DM is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5821.html" rel="external">"Management of type 2 diabetes mellitus in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – T2DM is distinguished from other causes of diabetes, such as type 1 diabetes mellitus (T1DM), by the clinical presentation and history. Clinical features suggesting T2DM are the presence of overweight/obesity, signs and/or symptoms of insulin resistance (such as acanthosis nigricans, hypertension, dyslipidemia, and polycystic ovary syndrome [PCOS]), positive family history, and being a member of a high-risk racial/ethnic group  (<a class="graphic graphic_table graphicRef59370" href="/z/d/graphic/59370.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef83072" href="/z/d/graphic/83072.html" rel="external">table 7</a>). Pancreatic autoantibodies are negative in most but not all patients with clinical features of T2DM. (See <a class="local">'Type 2 versus type 1 diabetes'</a> above and <a class="local">'Other causes of diabetes'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Weiss R, Caprio S, Trombetta M, et al. Beta-cell function across the spectrum of glucose tolerance in obese youth. Diabetes 2005; 54:1735.</a></li><li><a class="nounderline abstract_t">Elder DA, Hornung LN, Herbers PM, et al. Rapid deterioration of insulin secretion in obese adolescents preceding the onset of type 2 diabetes. J Pediatr 2015; 166:672.</a></li><li><a class="nounderline abstract_t">Divers J, Mayer-Davis EJ, Lawrence JM, et al. Trends in Incidence of Type 1 and Type 2 Diabetes Among Youths - Selected Counties and Indian Reservations, United States, 2002-2015. MMWR Morb Mortal Wkly Rep 2020; 69:161.</a></li><li><a class="nounderline abstract_t">Urakami T, Kubota S, Nitadori Y, et al. Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area. Diabetes Care 2005; 28:1876.</a></li><li><a class="nounderline abstract_t">Likitmaskul S, Kiattisathavee P, Chaichanwatanakul K, et al. Increasing prevalence of type 2 diabetes mellitus in Thai children and adolescents associated with increasing prevalence of obesity. J Pediatr Endocrinol Metab 2003; 16:71.</a></li><li><a class="nounderline abstract_t">Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr 2005; 146:693.</a></li><li class="breakAll">International Diabetes Federation. IDF Diabetes Atlas 2021: IDF Atlas 10th edition. Available at: https://diabetesatlas.org/atlas/tenth-edition/ (Accessed on January 18, 2022).</li><li><a class="nounderline abstract_t">Lee JM. Why young adults hold the key to assessing the obesity epidemic in children. Arch Pediatr Adolesc Med 2008; 162:682.</a></li><li><a class="nounderline abstract_t">Lee JM, Okumura MJ, Freed GL, et al. Trends in hospitalizations for diabetes among children and young adults: United States, 1993 2004. Diabetes Care 2007; 30:3035.</a></li><li><a class="nounderline abstract_t">Ogden CL, Carroll MD, Lawman HG, et al. Trends in Obesity Prevalence Among Children and Adolescents in the United States, 1988-1994 Through 2013-2014. JAMA 2016; 315:2292.</a></li><li><a class="nounderline abstract_t">Dabelea D, Mayer-Davis EJ, Saydah S, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 2014; 311:1778.</a></li><li><a class="nounderline abstract_t">Andes LJ, Cheng YJ, Rolka DB, et al. Prevalence of Prediabetes Among Adolescents and Young Adults in the United States, 2005-2016. JAMA Pediatr 2020; 174:e194498.</a></li><li><a class="nounderline abstract_t">Awa WL, Fach E, Krakow D, et al. Type 2 diabetes from pediatric to geriatric age: analysis of gender and obesity among 120,183 patients from the German/Austrian DPV database. Eur J Endocrinol 2012; 167:245.</a></li><li><a class="nounderline abstract_t">Liu LL, Lawrence JM, Davis C, et al. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. Pediatr Diabetes 2010; 11:4.</a></li><li><a class="nounderline abstract_t">Tirosh A, Shai I, Afek A, et al. Adolescent BMI trajectory and risk of diabetes versus coronary disease. N Engl J Med 2011; 364:1315.</a></li><li><a class="nounderline abstract_t">Freedman DS, Srinivasan SR, Burke GL, et al. Relation of body fat distribution to hyperinsulinemia in children and adolescents: the Bogalusa Heart Study. Am J Clin Nutr 1987; 46:403.</a></li><li><a class="nounderline abstract_t">Caprio S, Hyman LD, Limb C, et al. Central adiposity and its metabolic correlates in obese adolescent girls. Am J Physiol 1995; 269:E118.</a></li><li><a class="nounderline abstract_t">HEALTHY Study Group, Foster GD, Linder B, et al. A school-based intervention for diabetes risk reduction. N Engl J Med 2010; 363:443.</a></li><li><a class="nounderline abstract_t">Barnett AH, Eff C, Leslie RD, Pyke DA. Diabetes in identical twins. A study of 200 pairs. Diabetologia 1981; 20:87.</a></li><li><a class="nounderline abstract_t">Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 2000; 136:664.</a></li><li><a class="nounderline abstract_t">Copeland KC, Zeitler P, Geffner M, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab 2011; 96:159.</a></li><li><a class="nounderline abstract_t">Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes 2000; 49:2201.</a></li><li><a class="nounderline abstract_t">Alberti G, Zimmet P, Shaw J, et al. Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care 2004; 27:1798.</a></li><li><a class="nounderline abstract_t">Bell RA, Mayer-Davis EJ, Beyer JW, et al. Diabetes in non-Hispanic white youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009; 32 Suppl 2:S102.</a></li><li><a class="nounderline abstract_t">Dabelea D, DeGroat J, Sorrelman C, et al. Diabetes in Navajo youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009; 32 Suppl 2:S141.</a></li><li><a class="nounderline abstract_t">Mayer-Davis EJ, Beyer J, Bell RA, et al. Diabetes in African American youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009; 32 Suppl 2:S112.</a></li><li><a class="nounderline abstract_t">Liu LL, Yi JP, Beyer J, et al. Type 1 and Type 2 diabetes in Asian and Pacific Islander U.S. youth: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009; 32 Suppl 2:S133.</a></li><li><a class="nounderline abstract_t">Lawrence JM, Mayer-Davis EJ, Reynolds K, et al. Diabetes in Hispanic American youth: prevalence, incidence, demographics, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009; 32 Suppl 2:S123.</a></li><li><a class="nounderline abstract_t">Dean HJ, Young TK, Flett B, Wood-Steiman P. Screening for type-2 diabetes in aboriginal children in northern Canada. Lancet 1998; 352:1523.</a></li><li><a class="nounderline abstract_t">Kim C, McHugh C, Kwok Y, Smith A. Type 2 diabetes mellitus in Navajo adolescents. West J Med 1999; 170:210.</a></li><li><a class="nounderline abstract_t">Savage PJ, Bennett PH, Senter RG, Miller M. High prevalence of diabetes in young Pima Indians: evidence of phenotypic variation in a genetically isolated population. Diabetes 1979; 28:937.</a></li><li><a class="nounderline abstract_t">Gahagan S, Silverstein J, American Academy of Pediatrics Committee on Native American Child Health, American Academy of Pediatrics Section on Endocrinology. Prevention and treatment of type 2 diabetes mellitus in children, with special emphasis on American Indian and Alaska Native children. American Academy of Pediatrics Committee on Native American Child Health. Pediatrics 2003; 112:e328.</a></li><li class="breakAll">United States Centers for Disease Control: National Diabetes Statistics Report, 2014. Available at: https://www.cdc.gov/diabetes/data/statistics/2014StatisticsReport.html (Accessed on June 08, 2017).</li><li><a class="nounderline abstract_t">Powell J, Isom S, Divers J, et al. Increasing burden of type 2 diabetes in Navajo youth: The SEARCH for diabetes in youth study. Pediatr Diabetes 2019; 20:815.</a></li><li><a class="nounderline abstract_t">Arslanian S, Suprasongsin C. Differences in the in vivo insulin secretion and sensitivity of healthy black versus white adolescents. J Pediatr 1996; 129:440.</a></li><li><a class="nounderline abstract_t">Arslanian SA. Metabolic differences between Caucasian and African-American children and the relationship to type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2002; 15 Suppl 1:509.</a></li><li><a class="nounderline abstract_t">Danadian K, Balasekaran G, Lewy V, et al. Insulin sensitivity in African-American children with and without family history of type 2 diabetes. Diabetes Care 1999; 22:1325.</a></li><li><a class="nounderline abstract_t">Svec F, Nastasi K, Hilton C, et al. Black-white contrasts in insulin levels during pubertal development. The Bogalusa Heart Study. Diabetes 1992; 41:313.</a></li><li><a class="nounderline abstract_t">Banerji MA. Impaired beta-cell and alpha-cell function in African-American children with type 2 diabetes mellitus--"Flatbush diabetes". J Pediatr Endocrinol Metab 2002; 15 Suppl 1:493.</a></li><li><a class="nounderline abstract_t">Cruz ML, Weigensberg MJ, Huang TT, et al. The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity. J Clin Endocrinol Metab 2004; 89:108.</a></li><li><a class="nounderline abstract_t">Baranowski T, Cooper DM, Harrell J, et al. Presence of diabetes risk factors in a large U.S. eighth-grade cohort. Diabetes Care 2006; 29:212.</a></li><li><a class="nounderline abstract_t">Goran MI, Bergman RN, Avila Q, et al. Impaired glucose tolerance and reduced beta-cell function in overweight Latino children with a positive family history for type 2 diabetes. J Clin Endocrinol Metab 2004; 89:207.</a></li><li><a class="nounderline abstract_t">Ball GD, Huang TT, Gower BA, et al. Longitudinal changes in insulin sensitivity, insulin secretion, and beta-cell function during puberty. J Pediatr 2006; 148:16.</a></li><li><a class="nounderline abstract_t">Kelsey MM, Severn C, Hilkin AM, et al. Puberty Is Associated with a Rising Hemoglobin A1c, Even in Youth with Normal Weight. J Pediatr 2021; 230:244.</a></li><li><a class="nounderline abstract_t">Kelsey MM, Pyle L, Hilkin A, et al. The Impact of Obesity On Insulin Sensitivity and Secretion During Pubertal Progression: A Longitudinal Study. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Writing Group for the SEARCH for Diabetes in Youth Study Group, Dabelea D, Bell RA, et al. Incidence of diabetes in youth in the United States. JAMA 2007; 297:2716.</a></li><li><a class="nounderline abstract_t">Amiel SA, Sherwin RS, Simonson DC, et al. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 1986; 315:215.</a></li><li><a class="nounderline abstract_t">Pinhas-Hamiel O, Dolan LM, Daniels SR, et al. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr 1996; 128:608.</a></li><li><a class="nounderline abstract_t">Scott CR, Smith JM, Cradock MM, Pihoker C. Characteristics of youth-onset noninsulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis. Pediatrics 1997; 100:84.</a></li><li><a class="nounderline abstract_t">Teló GH, Dougher CE, Volkening LK, et al. Predictors of changing insulin dose requirements and glycaemic control in children, adolescents and young adults with Type 1 diabetes. Diabet Med 2018; 35:1355.</a></li><li><a class="nounderline abstract_t">Phillips DI, Barker DJ, Hales CN, et al. Thinness at birth and insulin resistance in adult life. Diabetologia 1994; 37:150.</a></li><li><a class="nounderline abstract_t">Forsén T, Eriksson J, Tuomilehto J, et al. The fetal and childhood growth of persons who develop type 2 diabetes. Ann Intern Med 2000; 133:176.</a></li><li><a class="nounderline abstract_t">Bhargava SK, Sachdev HS, Fall CH, et al. Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med 2004; 350:865.</a></li><li><a class="nounderline abstract_t">Chiavaroli V, Giannini C, D'Adamo E, et al. Insulin resistance and oxidative stress in children born small and large for gestational age. Pediatrics 2009; 124:695.</a></li><li><a class="nounderline abstract_t">Dabelea D, Mayer-Davis EJ, Lamichhane AP, et al. Association of intrauterine exposure to maternal diabetes and obesity with type 2 diabetes in youth: the SEARCH Case-Control Study. Diabetes Care 2008; 31:1422.</a></li><li><a class="nounderline abstract_t">Gungor N, Hannon T, Libman I, et al. Type 2 diabetes mellitus in youth: the complete picture to date. Pediatr Clin North Am 2005; 52:1579.</a></li><li><a class="nounderline abstract_t">Jefferies C, Carter P, Reed PW, et al. The incidence, clinical features, and treatment of type 2 diabetes in children &lt;15 yr in a population-based cohort from Auckland, New Zealand, 1995–2007. Pediatr Diabetes 2012; 13:294.</a></li><li><a class="nounderline abstract_t">Curran J, Hayward J, Sellers E, Dean H. Severe vulvovaginitis as a presenting problem of type 2 diabetes in adolescent girls: a case series. Pediatrics 2011; 127:e1081.</a></li><li><a class="nounderline abstract_t">Klingensmith GJ, Connor CG, Ruedy KJ, et al. Presentation of youth with type 2 diabetes in the Pediatric Diabetes Consortium. Pediatr Diabetes 2016; 17:266.</a></li><li><a class="nounderline abstract_t">Dabelea D, Rewers A, Stafford JM, et al. Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study. Pediatrics 2014; 133:e938.</a></li><li><a class="nounderline abstract_t">Sapru A, Gitelman SE, Bhatia S, et al. Prevalence and characteristics of type 2 diabetes mellitus in 9-18 year-old children with diabetic ketoacidosis. J Pediatr Endocrinol Metab 2005; 18:865.</a></li><li><a class="nounderline abstract_t">Chao LC, Vidmar AP, Georgia S. Spike in Diabetic Ketoacidosis Rates in Pediatric Type 2 Diabetes During the COVID-19 Pandemic. Diabetes Care 2021; 44:1451.</a></li><li><a class="nounderline abstract_t">Shulman R, Nakhla M, Diong C, et al. Health Care Use Prior to Diabetes Diagnosis in Children Before and During COVID. Pediatrics 2022; 150.</a></li><li><a class="nounderline abstract_t">Magge SN, Wolf RM, Pyle L, et al. The Coronavirus Disease 2019 Pandemic is Associated with a Substantial Rise in Frequency and Severity of Presentation of Youth-Onset Type 2 Diabetes. J Pediatr 2022; 251:51.</a></li><li><a class="nounderline abstract_t">Pinhas-Hamiel O, Dolan LM, Zeitler PS. Diabetic ketoacidosis among obese African-American adolescents with NIDDM. Diabetes Care 1997; 20:484.</a></li><li><a class="nounderline abstract_t">Neufeld ND, Raffel LJ, Landon C, et al. Early presentation of type 2 diabetes in Mexican-American youth. Diabetes Care 1998; 21:80.</a></li><li><a class="nounderline abstract_t">Praveen PA, Hockett CW, Ong TC, et al. Diabetic ketoacidosis at diagnosis among youth with type 1 and type 2 diabetes: Results from SEARCH (United States) and YDR (India) registries. Pediatr Diabetes 2021; 22:40.</a></li><li><a class="nounderline abstract_t">Zeitler P, Haqq A, Rosenbloom A, et al. Hyperglycemic hyperosmolar syndrome in children: pathophysiological considerations and suggested guidelines for treatment. J Pediatr 2011; 158:9.</a></li><li><a class="nounderline abstract_t">Rosenbloom AL. Hyperglycemic hyperosmolar state: an emerging pediatric problem. J Pediatr 2010; 156:180.</a></li><li><a class="nounderline abstract_t">Morales AE, Rosenbloom AL. Death caused by hyperglycemic hyperosmolar state at the onset of type 2 diabetes. J Pediatr 2004; 144:270.</a></li><li><a class="nounderline abstract_t">Hollander AS, Olney RC, Blackett PR, Marshall BA. Fatal malignant hyperthermia-like syndrome with rhabdomyolysis complicating the presentation of diabetes mellitus in adolescent males. Pediatrics 2003; 111:1447.</a></li><li><a class="nounderline abstract_t">Fourtner SH, Weinzimer SA, Levitt Katz LE. Hyperglycemic hyperosmolar non-ketotic syndrome in children with type 2 diabetes*. Pediatr Diabetes 2005; 6:129.</a></li><li><a class="nounderline abstract_t">Carchman RM, Dechert-Zeger M, Calikoglu AS, Harris BD. A new challenge in pediatric obesity: pediatric hyperglycemic hyperosmolar syndrome. Pediatr Crit Care Med 2005; 6:20.</a></li><li><a class="nounderline abstract_t">Bhowmick SK, Levens KL, Rettig KR. Hyperosmolar hyperglycemic crisis: an acute life-threatening event in children and adolescents with type 2 diabetes mellitus. Endocr Pract 2005; 11:23.</a></li><li><a class="nounderline abstract_t">Arslanian S, Bacha F, Grey M, et al. Evaluation and Management of Youth-Onset Type 2 Diabetes: A Position Statement by the American Diabetes Association. Diabetes Care 2018; 41:2648.</a></li><li><a class="nounderline abstract_t">American Diabetes Association Professional Practice Committee. 14. Children and Adolescents: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022; 45:S208.</a></li><li><a class="nounderline abstract_t">Shah AS, Zeitler PS, Wong J, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents. Pediatr Diabetes 2022; 23:872.</a></li><li><a class="nounderline abstract_t">American Diabetes Association Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022; 45:S17.</a></li><li><a class="nounderline abstract_t">American Diabetes Association Professional Practice Committee. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022; 45:S39.</a></li><li><a class="nounderline abstract_t">Kapadia C, Zeitler P, Drugs and Therapeutics Committee of the Pediatric Endocrine Society. Hemoglobin A1c measurement for the diagnosis of Type 2 diabetes in children. Int J Pediatr Endocrinol 2012; 2012:31.</a></li><li><a class="nounderline abstract_t">International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32:1327.</a></li><li><a class="nounderline abstract_t">Wallace AS, Wang D, Shin JI, Selvin E. Screening and Diagnosis of Prediabetes and Diabetes in US Children and Adolescents. Pediatrics 2020; 146.</a></li><li><a class="nounderline abstract_t">Lee JM, Wu EL, Tarini B, et al. Diagnosis of diabetes using hemoglobin A1c: should recommendations in adults be extrapolated to adolescents? J Pediatr 2011; 158:947.</a></li><li><a class="nounderline abstract_t">Nguyen QM, Srinivasan SR, Xu JH, et al. Fasting plasma glucose levels within the normoglycemic range in childhood as a predictor of prediabetes and type 2 diabetes in adulthood: the Bogalusa Heart Study. Arch Pediatr Adolesc Med 2010; 164:124.</a></li><li><a class="nounderline abstract_t">DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37:667.</a></li><li><a class="nounderline abstract_t">Shaw JE, Zimmet PZ, McCarty D, de Courten M. Type 2 diabetes worldwide according to the new classification and criteria. Diabetes Care 2000; 23 Suppl 2:B5.</a></li><li><a class="nounderline abstract_t">Libman IM, Barinas-Mitchell E, Bartucci A, et al. Reproducibility of the oral glucose tolerance test in overweight children. J Clin Endocrinol Metab 2008; 93:4231.</a></li><li><a class="nounderline abstract_t">Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 2003; 26:977.</a></li><li><a class="nounderline abstract_t">Wenzlau JM, Moua O, Sarkar SA, et al. SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Ann N Y Acad Sci 2008; 1150:256.</a></li><li><a class="nounderline abstract_t">Klingensmith GJ, Pyle L, Arslanian S, et al. The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study. Diabetes Care 2010; 33:1970.</a></li><li><a class="nounderline abstract_t">Dabelea D, Pihoker C, Talton JW, et al. Etiological approach to characterization of diabetes type: the SEARCH for Diabetes in Youth Study. Diabetes Care 2011; 34:1628.</a></li><li><a class="nounderline abstract_t">Redondo MJ, Connor CG, Ruedy KJ, et al. Pediatric Diabetes Consortium Type 1 Diabetes New Onset (NeOn) Study: factors associated with HbA1c levels one year after diagnosis. Pediatr Diabetes 2014; 15:294.</a></li><li><a class="nounderline abstract_t">Libman IM, Pietropaolo M, Arslanian SA, et al. Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes. Diabetes Care 2003; 26:2871.</a></li><li><a class="nounderline abstract_t">Patterson CC, Dahlquist GG, Gyürüs E, et al. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009; 373:2027.</a></li><li><a class="nounderline abstract_t">Silverstein J, Klingensmith G, Copeland K, et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005; 28:186.</a></li><li><a class="nounderline abstract_t">Pihoker C, Gilliam LK, Ellard S, et al. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth. J Clin Endocrinol Metab 2013; 98:4055.</a></li><li><a class="nounderline abstract_t">Shepherd M, Shields B, Hammersley S, et al. Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes. Diabetes Care 2016; 39:1879.</a></li><li><a class="nounderline abstract_t">Riddle MC, Philipson LH, Rich SS, et al. Monogenic Diabetes: From Genetic Insights to Population-Based Precision in Care. Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2020; 43:3117.</a></li><li><a class="nounderline abstract_t">Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30:753.</a></li><li><a class="nounderline abstract_t">Galderisi A, Giannini C, Weiss R, et al. Trajectories of changes in glucose tolerance in a multiethnic cohort of obese youths: an observational prospective analysis. Lancet Child Adolesc Health 2018; 2:726.</a></li><li><a class="nounderline abstract_t">Quinn SM, Baur LA, Garnett SP, Cowell CT. Treatment of clinical insulin resistance in children: a systematic review. Obes Rev 2010; 11:722.</a></li><li><a class="nounderline abstract_t">van der Aa MP, Elst MA, van de Garde EM, et al. Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. Nutr Diabetes 2016; 6:e228.</a></li><li><a class="nounderline abstract_t">Wiegand S, l'Allemand D, Hübel H, et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. Eur J Endocrinol 2010; 163:585.</a></li><li><a class="nounderline abstract_t">RISE Consortium. Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care 2018; 41:1717.</a></li><li><a class="nounderline abstract_t">RISE Consortium. Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp. Diabetes Care 2018; 41:1696.</a></li><li><a class="nounderline abstract_t">RISE Consortium. Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: II. Observations Using the Oral Glucose Tolerance Test. Diabetes Care 2018; 41:1707.</a></li><li><a class="nounderline abstract_t">Buse JB, D'Alessio DA, Riddle MC. Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes? Diabetes Care 2018; 41:1560.</a></li><li><a class="nounderline abstract_t">ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367:319.</a></li></ol></div><div id="topicVersionRevision">Topic 5820 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15919795" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Beta-cell function across the spectrum of glucose tolerance in obese youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25557969" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Rapid deterioration of insulin secretion in obese adolescents preceding the onset of type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32053581" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Trends in Incidence of Type 1 and Type 2 Diabetes Among Youths - Selected Counties and Indian Reservations, United States, 2002-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16043726" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12585343" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Increasing prevalence of type 2 diabetes mellitus in Thai children and adolescents associated with increasing prevalence of obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15870677" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The global spread of type 2 diabetes mellitus in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15870677" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The global spread of type 2 diabetes mellitus in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18606940" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Why young adults hold the key to assessing the obesity epidemic in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17728482" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Trends in hospitalizations for diabetes among children and young adults: United States, 1993 2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27272581" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Trends in Obesity Prevalence Among Children and Adolescents in the United States, 1988-1994 Through 2013-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24794371" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31790544" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prevalence of Prediabetes Among Adolescents and Young Adults in the United States, 2005-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22645200" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Type 2 diabetes from pediatric to geriatric age: analysis of gender and obesity among 120,183 patients from the German/Austrian DPV database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19473302" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21470009" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Adolescent BMI trajectory and risk of diabetes versus coronary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3307372" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Relation of body fat distribution to hyperinsulinemia in children and adolescents: the Bogalusa Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7631766" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Central adiposity and its metabolic correlates in obese adolescent girls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20581420" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A school-based intervention for diabetes risk reduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7193616" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Diabetes in identical twins. A study of 200 pairs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10802501" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20962021" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11118026" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Parental transmission of type 2 diabetes: the Framingham Offspring Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220270" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246575" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Diabetes in non-Hispanic white youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246579" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Diabetes in Navajo youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246576" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Diabetes in African American youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246578" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Type 1 and Type 2 diabetes in Asian and Pacific Islander U.S. youth: the SEARCH for Diabetes in Youth Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246577" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Diabetes in Hispanic American youth: prevalence, incidence, demographics, and clinical characteristics: the SEARCH for Diabetes in Youth Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9820307" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Screening for type-2 diabetes in aboriginal children in northern Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10344174" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Type 2 diabetes mellitus in Navajo adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/478185" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : High prevalence of diabetes in young Pima Indians: evidence of phenotypic variation in a genetically isolated population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14523221" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prevention and treatment of type 2 diabetes mellitus in children, with special emphasis on American Indian and Alaska Native children. American Academy of Pediatrics Committee on Native American Child Health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14523221" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prevention and treatment of type 2 diabetes mellitus in children, with special emphasis on American Indian and Alaska Native children. American Academy of Pediatrics Committee on Native American Child Health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31260152" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Increasing burden of type 2 diabetes in Navajo youth: The SEARCH for diabetes in youth study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8804335" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Differences in the in vivo insulin secretion and sensitivity of healthy black versus white adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12017225" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Metabolic differences between Caucasian and African-American children and the relationship to type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10480778" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Insulin sensitivity in African-American children with and without family history of type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1551490" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Black-white contrasts in insulin levels during pubertal development. The Bogalusa Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12017222" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Impaired beta-cell and alpha-cell function in African-American children with type 2 diabetes mellitus--"Flatbush diabetes".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14715836" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16443862" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Presence of diabetes risk factors in a large U.S. eighth-grade cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14715851" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Impaired glucose tolerance and reduced beta-cell function in overweight Latino children with a positive family history for type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16423592" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Longitudinal changes in insulin sensitivity, insulin secretion, and beta-cell function during puberty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33300876" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Puberty Is Associated with a Rising Hemoglobin A1c, Even in Youth with Normal Weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31996919" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The Impact of Obesity On Insulin Sensitivity and Secretion During Pubertal Progression: A Longitudinal Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17595272" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Incidence of diabetes in youth in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3523245" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8627431" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Increased incidence of non-insulin-dependent diabetes mellitus among adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9200365" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Characteristics of youth-onset noninsulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29855077" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Predictors of changing insulin dose requirements and glycaemic control in children, adolescents and young adults with Type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8163048" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Thinness at birth and insulin resistance in adult life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10906831" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The fetal and childhood growth of persons who develop type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14985484" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19651586" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Insulin resistance and oxidative stress in children born small and large for gestational age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18375420" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Association of intrauterine exposure to maternal diabetes and obesity with type 2 diabetes in youth: the SEARCH Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16301084" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Type 2 diabetes mellitus in youth: the complete picture to date.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22646236" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The incidence, clinical features, and treatment of type 2 diabetes in children&lt;15 yr in a population-based cohort from Auckland, New Zealand, 1995–2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21402639" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Severe vulvovaginitis as a presenting problem of type 2 diabetes in adolescent girls: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25951940" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Presentation of youth with type 2 diabetes in the Pediatric Diabetes Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24685959" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16279364" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prevalence and characteristics of type 2 diabetes mellitus in 9-18 year-old children with diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33905347" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Spike in Diabetic Ketoacidosis Rates in Pediatric Type 2 Diabetes During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35945681" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Health Care Use Prior to Diabetes Diagnosis in Children Before and During COVID.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35985535" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The Coronavirus Disease 2019 Pandemic is Associated with a Substantial Rise in Frequency and Severity of Presentation of Youth-Onset Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9096965" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Diabetic ketoacidosis among obese African-American adolescents with NIDDM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9538974" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Early presentation of type 2 diabetes in Mexican-American youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31943641" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Diabetic ketoacidosis at diagnosis among youth with type 1 and type 2 diabetes: Results from SEARCH (United States) and YDR (India) registries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21035820" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Hyperglycemic hyperosmolar syndrome in children: pathophysiological considerations and suggested guidelines for treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20105637" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Hyperglycemic hyperosmolar state: an emerging pediatric problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14760275" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Death caused by hyperglycemic hyperosmolar state at the onset of type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12777570" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Fatal malignant hyperthermia-like syndrome with rhabdomyolysis complicating the presentation of diabetes mellitus in adolescent males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16109068" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Hyperglycemic hyperosmolar non-ketotic syndrome in children with type 2 diabetes*.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15636654" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A new challenge in pediatric obesity: pediatric hyperglycemic hyperosmolar syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16033732" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Hyperosmolar hyperglycemic crisis: an acute life-threatening event in children and adolescents with type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30425094" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Evaluation and Management of Youth-Onset Type 2 Diabetes: A Position Statement by the American Diabetes Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34964865" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : 14. Children and Adolescents: Standards of Medical Care in Diabetes-2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36161685" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34964875" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34964876" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes-2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23256825" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Hemoglobin A1c measurement for the diagnosis of Type 2 diabetes in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19502545" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32778539" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Screening and Diagnosis of Prediabetes and Diabetes in US Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21195416" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Diagnosis of diabetes using hemoglobin A1c: should recommendations in adults be extrapolated to adolescents?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20124140" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Fasting plasma glucose levels within the normoglycemic range in childhood as a predictor of prediabetes and type 2 diabetes in adulthood: the Bogalusa Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3289989" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10860184" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Type 2 diabetes worldwide according to the new classification and criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18713820" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Reproducibility of the oral glucose tolerance test in overweight children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12663559" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19120307" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20519658" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21636800" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Etiological approach to characterization of diabetes type: the SEARCH for Diabetes in Youth Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23889707" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Pediatric Diabetes Consortium Type 1 Diabetes New Onset (NeOn) Study: factors associated with HbA1c levels one year after diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14514594" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19481249" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15616254" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23771925" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27271189" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33560999" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Monogenic Diabetes: From Genetic Insights to Population-Based Precision in Care. Reflections From a Diabetes Care Editors' Expert Forum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17327355" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Impaired fasting glucose and impaired glucose tolerance: implications for care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30236381" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Trajectories of changes in glucose tolerance in a multiethnic cohort of obese youths: an observational prospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20003069" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Treatment of clinical insulin resistance in children: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27571249" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20639355" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29941500" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Impact of Insulin and Metformin Versus Metformin Alone onβ-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29941497" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29941498" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: II. Observations Using the Oral Glucose Tolerance Test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29941499" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22686416" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Basal insulin and cardiovascular and other outcomes in dysglycemia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
